ATAI heads into its May 11 results with one of the most striking short-interest build-ups in its recent history — even as every analyst on the Street still holds a Buy rating.
Short sellers have turned sharply more aggressive over the past month. Short interest has climbed to nearly 12% of the free float — a 40% jump over the past 30 days. In absolute terms, that adds roughly 7.4 million shares to the short book since early April. The borrow market remains loose, with cost to borrow barely above 0.6% and availability showing no sign of a squeeze, but the one-month build itself is notable for a clinical-stage name still years from profitability.
Options traders tell a different story. The put/call ratio is running at 0.15, well below its 52-week high of 0.23 and modestly above its 20-day average of 0.12 — a reading that reflects broadly call-heavy positioning rather than hedging pressure. That divergence between short sellers building positions and options traders leaning toward calls is the clearest tension heading into the print. The ORTEX short score has drifted higher to 53.4, but it remains squarely mid-range and well off any extreme.
The analyst community has been uniformly constructive. Guggenheim lifted its target from $11 to $16 in mid-April. Canaccord Genuity raised its target to $15 shortly after. Deutsche Bank initiated coverage at Buy with a $12 target in late March. Every firm on the coverage list carries a Buy, with the consensus mean price target near $14 — more than 3x the current price of $4.03. That gap reflects the binary nature of the pipeline rather than near-term fundamental delivery. The bull case centres on phase 3 data for BPL-003, the mebufotenin nasal spray for treatment-resistant depression, and phase 2b results for VLS-01. Bears point to the long runway — phase 3 initiation for VLS-01 is not set until 2029 — and the near-certainty of dilutive capital raises along the way.
Institutional flows add a layer of nuance. ARK Investment Management added 1.3 million shares as recently as April 30. BlackRock initiated a new position of 2.8 million shares in the same period. Those are signals that sophisticated buyers are accumulating even as shorts build. Insider activity runs the other way: the Chief Medical Officer sold shares twice this year, most recently 42,000 shares in late April at $5.00. The net insider picture over 90 days is modest net selling.
The May 11 print will test whether the clinical progress visible in the pipeline warrants the sharp re-rating that analysts are pricing in — and whether the recent surge in short interest reflects well-founded scepticism about the capital and timeline required to get there.
See the live data behind this article on ORTEX.
Open ATAI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
